Fallopian Tube Tumor Mimicking Primary Gastrointestinal Malignancy.

Cureus

Surgery, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, USA.

Published: August 2020

A 67-year-old female patient positive for a mismatch repair gene mutation and history of serous carcinoma of the fallopian tube presented with a lower gastrointestinal bleed. Clinical workup was suggestive of a primary gastrointestinal malignancy. Pathological review after right hemicolectomy revealed the primary tumor was a fallopian tube carcinoma. Over the next few years, she presented with upper and lower gastrointestinal bleeds from a recurrent metastatic disease, which was from the primary fallopian tube cancer. Although serous carcinoma of the fallopian tube is not an uncommon diagnosis, it is unusual for it to present with symptoms of recurrent gastrointestinal bleed mimicking a primary gastrointestinal malignancy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494413PMC
http://dx.doi.org/10.7759/cureus.9795DOI Listing

Publication Analysis

Top Keywords

fallopian tube
20
primary gastrointestinal
12
gastrointestinal malignancy
12
mimicking primary
8
serous carcinoma
8
carcinoma fallopian
8
lower gastrointestinal
8
gastrointestinal bleed
8
gastrointestinal
6
fallopian
5

Similar Publications

Background: SL-172154 is a hexameric fusion protein adjoining the extracellular domain of SIRPα to the extracellular domain of CD40L via an inert IgG-derived Fc domain. In preclinical studies, a murine equivalent SIRPα-Fc-CD40L fusion protein provided superior antitumor immunity in comparison to CD47- and CD40-targeted antibodies. A first-in-human phase I trial of SL-172154 was conducted in patients with platinum-resistant ovarian cancer.

View Article and Find Full Text PDF

Purpose: The increase of oral tumor therapies (OTT) poses new challenges in patient care. Within CAMPA (Care improvement for advanced or metastatic breast and ovarian cancer patients treated with PARP-inhibitors), additional nursing support for patients treated with PARP-inhibitors was developed.

Methods: Additional nursing support (1 year) was evaluated in breast and gynecooncological cancer patients at an academic and a non-academic outreach center.

View Article and Find Full Text PDF

Introduction And Importance: Cystic endosalpingiosis is a rare, benign condition characterized by the presence of fallopian tube-like epithelium outside the fallopian tubes. It predominantly affects menopausal women and is often asymptomatic. Florid cystic endosalpingiosis, an unusual form, can mimic malignant ovarian masses, making accurate diagnosis crucial.

View Article and Find Full Text PDF

: Hysterosalpingography (HSG) is pivotal in delineating tubal pathology, but is associated with pain and exposure to ionizing radiation. This study investigated which reproductive factors predict HSG-identified tubal pathology. : From May 2016 to August 2023, 3322 infertile females with HSG (mean age 33.

View Article and Find Full Text PDF

Prolapsed fallopian tube to the vagina after hysterectomy a year ago: A case report.

Taiwan J Obstet Gynecol

January 2025

Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, Taichung 40203, Taiwan; Institute of Medicine, Chung Shan Medical University, Taichung 40203, Taiwan.

Objective: This case report aims to present a rare occurrence of fallopian tube prolapse into the vaginal vault following hysterectomy, underscoring the importance of recognizing this uncommon complication.

Case Report: A 45-year-old woman, with a history of hysterectomy for adenomyosis, presented with symptoms mimicking a vaginal tumor, including persistent discharge, abdominal pain, postcoital bleeding, and weight loss. Imaging raised concerns of malignancy, but surgery revealed a prolapsed fallopian tube with chronic inflammation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!